CD73 Inhibitor Compounds to Reduce Adenosine Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, infections, and neurodegenerative diseases are inadequate, particularly due to the immunosuppressive effects of CD73, which is overexpressed in various conditions and contributes to therapy resistance and immune evasion.
Innovation Solution
Development of compounds that inhibit CD73 activity, including pharmaceutical compositions targeting CD73 to reduce adenosine production, thereby enhancing immune response and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD73 is overexpressed to suppress immune response and promote tumor growth, then tumor progression and immune evasion are enhanced, but therapeutic efficacy is reduced
Solution Approach 1:
The patent converts the harmful immunosuppressive function of CD73 into a beneficial therapeutic target. By designing inhibitors that block CD73 activity, the patent transforms the enzyme's harmful role in immune evasion and tumor progression into a vulnerability that can be exploited for cancer therapy. The inhibitors convert the overexpressed CD73 from a protective mechanism for tumors into a target for therapeutic intervention, thereby converting harm into benefit.
Solution Approach 2:
The patent introduces small molecule inhibitors as intermediaries that mediate between the immune system and CD73. These compounds act as mediators that block the interaction between CD73 and its substrates (AMP, ADP), preventing the formation of immunosuppressive adenosine. The inhibitors serve as intermediary agents that disrupt the harmful signaling pathway without directly activating the immune system, thereby resolving the contradiction between tumor suppression and immune evasion.
2Reliability
If conventional chemotherapy and immunotherapy are used alone, then treatment simplicity is maintained, but therapy resistance develops due to CD73-mediated immunosuppression
Solution Approach 1:
The patent merges CD73 inhibition with conventional chemotherapy and immunotherapy into a combination treatment regimen. By combining the small molecule CD73 inhibitor with existing therapeutic agents, the patent creates a synergistic effect that overcomes therapy resistance. The merged treatment approach allows the inhibitors to enhance the efficacy of chemotherapy and immunotherapy by reversing CD73-mediated immunosuppression, thereby improving overall therapeutic reliability.
Solution Approach 2:
The patent develops CD73 inhibitors with universal applicability across multiple cancer types and therapeutic contexts. The small molecule compounds are designed to function as broad-spectrum anti-cancer agents that can be used in combination with various chemotherapy regimens and immunotherapies. This multi-functionality allows a single CD73 inhibitor to address therapy resistance in different cancer types without requiring cancer-specific modifications, thereby managing treatment complexity while improving efficacy.
3Reliability
If CD73 activity is inhibited to enhance immune response, then tumor sensitivity to therapy is improved, but potential off-target effects may occur
Solution Approach 1:
The patent applies local quality by designing CD73 inhibitors with high specificity for the CD73 enzyme at the molecular level. The small molecule compounds are structurally optimized to interact selectively with the active site of CD73, ensuring that inhibition occurs locally at the target enzyme without affecting other nucleotidases or cellular processes. This localized specificity enhances tumor sensitivity to therapy while minimizing off-target effects through precise molecular recognition.
Solution Approach 2:
The patent utilizes parameter changes by optimizing the chemical structure of the inhibitors to achieve the desired balance between efficacy and selectivity. By modifying parameters such as molecular size, functional groups, and binding affinity, the patent fine-tunes the inhibitors' properties to maximize CD73 inhibition while minimizing interactions with off-target proteins. These parameter optimizations ensure high tumor sensitivity with reduced potential for adverse effects.
Data Source
AI summary
Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.